Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ACP1 | P24666 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29716108 | 0.98 | MEN1 (0.54) | MEN1KMT2AALOX5ALDH1A1POLB | |
| SCHEMBL12852871 | 0.88 | ALOX5 (0.53) | MEN1KMT2AALOX5ALDH1A1MAPT | |
| SCHEMBL13600434 | 0.88 | ALOX5 (0.57) | MEN1KMT2AALOX5ALDH1A1MAPT | |
| SCHEMBL17785611 | 0.83 | MEN1 (0.51) | MEN1KMT2AALOX5ALDH1A1POLB | |
| SCHEMBL15329823 | 0.81 | ALOX5 (0.51) | MEN1KMT2AALOX5ALDH1A1MAPT | |
| SCHEMBL362241 | 0.81 | ALDH1A1 (0.56) | MEN1KMT2AALOX5ALDH1A1POLB | |
| SCHEMBL30410721 | 0.80 | CYP3A4 (0.52) | MEN1KMT2AALOX5ALDH1A1POLB | |
| SCHEMBL2301570 | 0.80 | MEN1 (0.49) | MEN1KMT2AALOX5ALDH1A1MAPT | |
| SCHEMBL29735373 | 0.80 | HTT (0.53) | MEN1KMT2AALOX5ALDH1A1POLB | |
| SCHEMBL1025493 | 0.80 | HTT (0.53) | MEN1KMT2AALOX5ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114716340-B | Preparation method of iopromide intermediate | 杭州微流汇科技有限公司 | 2023-11-14 | — | — | CN | claimed |
| CN-114716340-A | Preparation method of iopromide intermediate | 杭州微流汇科技有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-119060060-A | Imidazole-containing ALK2 kinase inhibitors | 拜奥克里斯特制药公司 | 2024-12-03 | — | — | CN | disclosed |
| US-20240376117-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-11-14 | — | — | US | disclosed |
| CN-110913855-B | Imidazole-containing ALK2 kinase inhibitors | 拜奥克里斯特制药公司 | 2024-09-03 | — | — | CN | disclosed |
| US-12054492-B2 | Imidazole-containing inhibitors of ALK2 kinase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| CN-114716340-B | Preparation method of iopromide intermediate | 杭州微流汇科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-114716340-B | Preparation method of iopromide intermediate | 杭州微流汇科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20230271975-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-08-31 | — | — | US | disclosed |
| US-20230271975-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-08-31 | — | — | US | disclosed |
| US-11661426-B2 | Imidazole-containing inhibitors of ALK2 kinase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| WO-2005079497-A2 | SUBSTITUTED FUSED BICYCLIC AMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
| US-6919356-B2 | N-substituted heterocyclic amines as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| US-20050153970-A1 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-07-14 | — | — | US | disclosed |
| EP-1545524-A2 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY. | Bristol-Myers Squibb Company (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005048932-A2 | N-UREIDOALKYL-AMINO COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20040082616-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-29 | — | — | US | disclosed |
| WO-2004028530-A1 | N-SUBSTITUTED HETEROCYCLIC AMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-08 | — | — | WO | disclosed |
| US-20040067935-A1 | N-substituted heterocyclic amines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-08 | — | — | US | disclosed |
| WO-2004024682-A2 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY. | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153970-A1 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | ACKR3, CCL11, GPR17 | MEN1 4758/4885KMT2A 4319/4885ALOX5 861/4885 |
| US-20230271975-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | ALK, ACVR2B, ACVR2A | MEN1 2350/4885KMT2A 906/4885ALOX5 3281/4885 |
| US-11661426-B2 | Imidazole-containing inhibitors of ALK2 kinase | ALK, ACVR2B, ACVR2A | MEN1 2350/4885KMT2A 906/4885ALOX5 3281/4885 |
| US-20040082616-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | ACKR3, CCL11, CCR2 | MEN1 4841/4885KMT2A 3851/4885ALOX5 1558/4885 |
| US-20240376117-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | ALK, ACVR2B, ACVR2A | MEN1 2350/4885KMT2A 906/4885ALOX5 3281/4885 |
| US-12054492-B2 | Imidazole-containing inhibitors of ALK2 kinase | ALK, ACVR2B, ACVR2A | MEN1 2350/4885KMT2A 906/4885ALOX5 3281/4885 |
| US-20040067935-A1 | N-substituted heterocyclic amines as modulators of chemokine receptor activity | CCL11, ACKR3, CCR7 | MEN1 3653/4885KMT2A 3340/4885ALOX5 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.